Tìm theo
Infliximab
Các tên gọi khác (1) :
  • Ig gamma-1 chain C region
antirheumatic agents, anti inflammatory agents non steroidal, dermatologic agents, gastrointestinal age
Thuốc Gốc
Biotech
CAS: 170277-31-3
ATC: L04AB02
ĐG : Centocor Ortho Biotech Inc. , http://www.centocororthobiotech.com
CTHH: C6428H9912N1694O1987S46
PTK: 144190.3000
Tumor necrosis factor (TNF-alpha) binding antibody (chimeric IgG1). It is composed of human constant and murine variable regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C6428H9912N1694O1987S46
Phân tử khối
144190.3000
Độ tan chảy
61 °C (FAB fragment), 71 °C (whole mAb)
Độ kỵ nước
-0.441
Điểm đẳng điện tích
8.25
Dược Lực Học : Infliximab is a chimeric human-murine anti-human tumor necrosis factor (TNF) monoclonal antibody. It binds to tumor necrosis factor alpha (TNFa) and inhibits binding of TNFa with its receptors. This reduces production of pro-inflammatory cytokines such as interleukins (IL) 1 and 6. This also limits leukocyte migration and expression of adhesion molecules by endothelial cells and leukocytes. Infliximab also limits the activation of neutrophil and eosinophil functional activity, reduces production of tissue degrading enzymes produced by synoviocytes and/or chondrocytes. Infliximab decreases synovitis and joint erosions in collagen-induced arthritis and allows eroded joints to heal.
Cơ Chế Tác Dụng : Tumor necrosis factor (TNF-alpha) binding antibody (chimeric IgG1). It is composed of human constant and murine variable regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion Infliximab neutralizes the biological activity of TNFa by binding with high affinity to the soluble and transmembrane forms of TNFa and inhibits binding of TNFa with its receptors. Infliximab does not neutralize TNFb (lymphotoxin a), a related cytokine that utilizes the same receptors as TNFa. TNFa activation normally induces the release of proinflammatory cytokines, the enhancement of leukocyte migration and activation of neutrophils among others. Neutralization of the biological activity of TNFa leads to an overall reduction in inflammation.
Dược Động Học :
▧ Absorption :
Onset of action occurs in about 2 weeks in Crohn's disease.
▧ Volume of Distribution :
3-6 L
▧ Metabolism :
Most likely removed by opsonization via the reticuloendothelial system when bound to T lymphocytes, or by human antimurine antibody production. Not metabolized by the CYP enzymes.
▧ Half Life :
9.5 days (7-12 days) in patients with Crohn's disease, plaque psoriasis and rheumatoid arthritis
Chỉ Định : To manage the signs and symptoms, as well as to induce and maintain clinical remission in adults with moderate to severe active Crohn's disease or ulcerative colitis. Also used to manage signs and symptoms of rheumatoid arthritis (in conjunction with methotrexate), ankylosing spondylitis, psoriatic arthritis, and juvenile arthritis.
Tương Tác Thuốc :
  • Abatacept The combination shoould be avoided as there have been reports of increased risk of serious infections.
  • Adalimumab Both bind to TNF alfa and thus combination results in enhanced immunosuppressive effect. It is recommended that simultaneous use of both agents be avoided.
  • Anakinra Combination may enhance the toxic effect of Anakinra and should be avoided otherwise there may be an increased risk of infection
  • Canakinumab Avoid combination due to increased risk of infection as anti-TNF agents enhance adverse effects of Canakinumab.
  • Certolizumab pegol Avoid combination because anti-TNF agents increase adverse effects of certolizumab pegol
  • Denosumab Therapy should be monitored when combination is initiated as there may be an increase in serious infections.
  • Etanercept Avoid combination because etanercept may increase immunosuppressive effects of infliximab.
  • golimumab Avoid combination with infliximab due to the potential increased immunosuppression of infliximab.
  • Leflunomide Therapy modification should be considered in order to reduce the risk of hematologic toxicities.
  • Natalizumab Increase adverse effects of natalizumab. Avoid combination
  • Pimecrolimus Pimecrolimus enhances the adverse effects of immune suppressants thus the combination should be avoided.
  • Rilonacept Anti-TNF alfa agents enhance adverse effects of rilonacept thus combination should be avoided.
  • Roflumilast Roflumilast enhances the adverse effects of immune suppressants thus a therapy modification should be considered.
  • Sipuleucel-T Monitoring is required because immunosuppressants can decrease the therapeutic effect of Sipuleucel-T.
  • Tacrolimus Avoid combination because of risk of enhance adverse effects of immunosuppressants
  • Tocilizumab Avoid combination because enhanced immunosuppression by anti-TNF agents.
  • Tofacitinib Avoid combination with infliximab and other anti-TNF drugs due to the potential enhancement of tofacitinib related adverse effects.
  • Trastuzumab Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Liều Lượng & Cách Dùng : Powder, for solution - Intravenous
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty : Centocor Inc
    Sản phẩm biệt dược : Remicade
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00065
GenBank
http://www.ncbi.nlm.nih.gov/nuccore/J00228
PharmGKB
http://www.pharmgkb.org/drug/PA452639
Wikipedia
http://en.wikipedia.org/wiki/Infliximab
RxList
http://www.rxlist.com/cgi/generic3/infliximab.htm
Drugs.com
http://www.drugs.com/cdi/infliximab.html
... loading
... loading